Sort by
Refine Your Search
-
/or flammable substances. It is an intermediate for a range of materials. The alternative plasma approach offers, from a process safety viewpoint, an inherent safer alternative by reducing process
-
corneal dystrophy or iatrogenic damage after surgery accelerate their loss, leading to corneal endothelial disease. The characteristic corneal oedema and opacity are a leading cause of blindness. The state
-
the project in terms of legitimacy and efficacy. Key questions include examining the influence of AI metaphors on technical and policy discourse and their societal impact, and identifying alternative
-
employment conditions through a collective labor agreement (CAO) choice model. As Maastricht University, we offer various other excellent secondary employment conditions. These include a good pension scheme
-
compensation hours, an additional 12 days will be added. Furthermore, you can personalize your employment conditions through a collective labor agreement (CAO) choice model. As Maastricht University, we offer
-
agreement (CAO) choice model. As Maastricht University, we offer various other excellent secondary employment conditions. These include a good pension scheme with the ABP and the opportunity for UM employees
-
, showing effective teamwork within the organization. Requirements Specific Requirements Selection Criteria: A highly motivated candidate. Scientific knowledge and interest in the field of neuroscience and
-
, an additional 12 days will be added. Furthermore, you can personalize your employment conditions through a collective labor agreement (CAO) choice model. As Maastricht University, we offer various other excellent
-
days will be added. Furthermore, you can personalize your employment conditions through a collective labor agreement (CAO) choice model. As Maastricht University, we offer various other excellent
-
pharmacological treatment options that delay or halt the progression of OA. In this project, we aim to identify unique small-molecule-based disease-modifying drugs (DMOADs) that can provide a biomolecular basis for